Clemons, Mark <br/><br/>
A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.  [electronic resource] 

 -  Breast cancer research and treatment  Mar 2008 
 - 79-85 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>0167-6806 
<br/><br/><label>Standard No.: </label>10.1007/s10549-007-9583-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Bone Density Conservation Agents--administration & dosage<br/>Bone Diseases--drug therapy<br/>Bone Neoplasms--drug therapy<br/>Bone and Bones--drug effects<br/>Breast Neoplasms--complications<br/>Diphosphonates--administration & dosage<br/>Female<br/>Humans<br/>Ibandronic Acid<br/>Infusions, Intravenous<br/>Middle Aged<br/>Pain--drug therapy<br/>Palliative Care<br/>Pamidronate